Skip to main content

Webinars

  • Mark Flood, BMLSc ,
    Application Specialist, Pathology Associates, Pathlab Bay of Plenty, New Zealand

The Value of an RTU

Novocastra p16 antibody demonstrated an agreement of 98% with the Roche p16 antibody The study compared the percentage agreement rates of Novocastra’s p16 (6H12) IVD solution with Roche CINtec® Histology p16 assay on 170 oropharyngeal cancer cases.

NEW STUDY SHOWS BOND-III UP TO 40% FASTER THAN BENCHMARK ULTRA In a recent study, the Leica Biosystems BOND-III was found to complete cases up to 100 minutes faster than the Roche Tissue Diagnostics BenchMark ULTRA. The study examines the panel turnaround...